Results 91 to 100 of about 1,245,973 (360)

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

open access: yesMolecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani   +14 more
wiley   +1 more source

Surgical treatment of intracranial epithelioid hemangioendothelioma: a case report

open access: yesСеченовский вестник, 2023
Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular neoplasm with an intermediate pattern of malignancy between benign neoplasms and angiosarcomas.
A. V. Gavrjushin, D. M. Chelushkin
doaj   +1 more source

Adult Pure Yolk Sac Tumor of The Testis. [PDF]

open access: yes, 2012
Adult pure yolk sac tumor (YST) is extremely rare. In childhood pure yolk sac tumors are most frequently seen, whereas component of mixed germ cell testicular tumors observed in adults.
Jagtap, SV, Kshirsagar, AY, Nikumbh, DB
core  

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma [PDF]

open access: yes, 2017
Aims: CDX2 is widely used as a sensitive and specific immunomarker for colorectal carcinoma (CRC) but neither this sensitivity nor specificity is absolute. This study is the first known comparison of CDX1 and A33 against CDX2 as immunomarkers for CRC.
Adamczyk, Lukasz A.   +5 more
core   +1 more source

KCNQ1OT1 promotes melanoma growth and metastasis

open access: yesAging, 2018
Melanoma is the deadliest cutaneous neoplasm. To prevent metastasis, early diagnosis and surgical treatment is vital. Long non-coding RNAs (lncRNAs) may serve as biomarkers and therapeutic targets in tumors.
B. Guo   +4 more
semanticscholar   +1 more source

Pancreatic metastasis of Merkel-cell carcinoma: a rare neoplasm of the pancreas

open access: yesRevista Española de Enfermedades Digestivas, 2020
Only 2-3.9% of pancreatic malignancies represent metastases from other sites, the most common origins being the lungs, kidneys, and gastrointestinal tract. Differentiating between primary and secondary lesions may be challenging with imaging techniques but EUS-guided FNA is a safe, accurate procedure for obtaining a tissue diagnosis. We report the case
María Josefa Sánchez Fernández   +2 more
openaire   +2 more sources

MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NFκB axis

open access: yesMolecular Oncology, EarlyView.
mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).
Jesús García‐Castillo   +8 more
wiley   +1 more source

Aggressive Behaviour of Metastatic Melanoma in a Patient with Neurofibromatosis Type 1

open access: yesCase Reports in Surgery, 2015
Malignant melanoma is a common skin neoplasm bearing poor prognosis when presenting with metastases. Rarely melanoma metastases present without an identifiable primary cutaneous lesion despite exhaustive workup.
Robert W. Foley   +3 more
doaj   +1 more source

Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas [PDF]

open access: yes, 2019
The bile duct system and pancreas show many similarities due to their anatomical proximity and common embryological origin. Consequently, preneoplastic and neoplastic lesions of the bile duct and pancreas share analogies in terms of molecular ...
Alvaro, D   +10 more
core   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy